



Click [here](#) for high-res photos

Press Release

Immediate Release

HKSTP and Two Medical Faculties of Universities to Showcase Hong Kong's Biotech Strength at BIO 2025 in Boston
Highlight Innovations and Potential in Life and Health Technologies from 16 Park Companies

(Hong Kong, June 6, 2025) – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, will lead a delegation of 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19, 2025. For the first time, Hong Kong's two leading medical faculties—the **LKS Faculty of Medicine at The University of Hong Kong (HKU)** and the **Faculty of Medicine at The Chinese University of Hong Kong (CUHK)**—will join the delegation. The goal is to showcase Hong Kong's exceptional strengths and innovative potential in the life and health sciences on a global stage. By engaging with leading international tech pioneers, the delegation aims to attract enterprises, talent, and investors, thereby further enhancing Hong Kong's status as a global biotech hub.

BIO 2025 brings together nearly 20,000 biotechnology industry leaders and professionals from approximately 70 countries and regions. The event covers comprehensive aspects of biotechnology, including research and development, clinical trials, manufacturing, business development, investment, and market commercialization.

Hong Kong has a strong foundation in scientific research and is home to world-class universities, which gives its life and health industry a competitive edge on the global stage. At the event, HKSTP will spotlight the remarkable research and innovations emerging from the park companies, highlighting Hong Kong's advanced technological capabilities. Representatives from both medical faculties will also attend BIO to promote deeper engagement on this international platform. The participation will demonstrate Hong Kong's remarkable achievements in the sector, attract business and investments opportunities, and further solidify Hong Kong's role as a leading global biotechnology hub.



Professor Chak-sing Lau, Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at HKU, stated: “Health technology is a crucial pillar of Hong Kong's innovation landscape. HKUMed is dedicated to translating research into breakthroughs in drug development, vaccinology and stem cell biotechnology, in particular. From pioneering a nasal COVID-19 vaccine for emergency use to developing novel needle-free, live-attenuated influenza vaccines, and the first Hong Kong prescription oral arsenic-trioxide leukaemia drug for global use, we also play a key role in operating the Greater Bay Area International Clinical Trial Institute. These achievements reflect the relentless efforts of our Faculty in fostering innovation and collaboration with leading research institutions from the Mainland and around the world. Local universities and industry stakeholders are excelling in their respective fields, and we look forward to efficient collaboration among the Government, industry, academia, and the research and investment sectors to position Hong Kong as an international hub for health and medical innovation.”

Professor Philip Chiu, Dean of Medicine at CUHK, said, “We are devoted to promoting clinical translation of cutting-edge technologies. Our Faculty pioneers in the application of innovative non-invasive diagnostic methods, precision medicine in oncology, advanced gut microbiome technology and medical robotics to address health challenges such as an ageing population and emerging infectious diseases. Our innovations not only consolidate Hong Kong’s position as an international health and medical innovation hub but also provide solutions to some of the global health issues. We look forward to showcasing our latest research output and innovations to leaders of different backgrounds from around the world, attracting more international collaboration opportunities, and thereby enhancing Hong Kong’s international image as a hub for life sciences and health technology.”

Albert Wong, Chief Executive Officer of HKSTP, said: “We are delighted to showcase once again Hong Kong’s biotechnology expertise and potential at BIO 2025. The participation of esteemed representatives from our top medical faculties highlights the depth of our research capabilities and the collaborative spirit that is driving our growth as a biotech powerhouse. Hong Kong’s strategic positioning as a gateway between Mainland China and the international community enables us to actively support startups in exploring overseas business and investment opportunities while fostering ties with local innovation ecosystems. By attracting high-potential startups to establish a presence in Hong Kong, along with top-tier scientific

talent and investment opportunities from around the world, we are solidifying Hong Kong's position as an international innovation and technology hub."

The delegation will participate in the 2025 Biomedical Pitch Competition on June 14, co-organized by the Boston Chinese Investment Club (BCIC) and supported by HKSTP. Three park companies advanced to the finals, competing for top honors. HKSTP also took part in this competition last year, where three participating companies successfully secured approximately HKD 80 million in investments.

The 16 Hong Kong companies attending BIO 2025 will showcase innovations spanning pharmaceuticals, gene editing, diagnostics, regenerative medicine, and more. These companies, supported by Incu-Bio Programme and Elite Programme of HKSTP, and the InnoHK initiative, highlight the remarkable range and depth of innovation thriving within Hong Kong's biotech ecosystem.

Highlighted Innovations include:

- **ARBELE** – Pioneering innovative immunotherapies to address unmet clinical needs in gastrointestinal cancers.
- **Beth Bioinformatics** – Empowering vaccine developers with cutting-edge technologies such as virus evolution prediction (e.g. Influenza & SARS-CoV-2), epitope screening and codon optimization to co-develop high-efficacy, longer-lasting and novel vaccine products.
- **Centre for Translational Stem Cell Biology (InnoHK)** – Pioneering patented Expanded Potential Stem Cell (EPSC) technology to drive innovation in regenerative medicine, drug screening, precision medicine and therapeutic applications.
- **DECODE CURE** – Monitors and predicts trends in COVID-19, influenza, and urban antibiotic resistance through wastewater microbial data testing and analysis.
- **GenEditBio** – Specializes in developing in vivo genome editing therapies (referred to as "DNA surgery") by discovering novel Cas nucleases and creating safe, efficient in vivo delivery technologies to treat genetic mutation-related diseases.
- **Immuno Cure** - Completed of a first-in-human novel therapeutic HIV vaccine, ICVAX, Phase I clinical trial with encouraging findings of exceptional safety and promising immunogenicity profiles. Their Innovative Immunotherapy – DNA medicines and



Page 4 of 7

antibody immunotherapies for the treatment of infectious diseases, inflammation, and cancers.

The delegation aims to establish strategic partnerships, attract investment, facilitate technology transfer, and enhance international collaboration at BIO 2025. It will further strengthen Hong Kong's role as a vibrant global biotechnology hub. Currently, Hong Kong Science Park is home to over 300 life and health technology companies. HKSTP provides comprehensive support, including incubation programmes, well-equipped laboratory facilities, and financial assistance to nurture startups and accelerate their commercialization.

Date:	June 16-19, 2025
Location:	Boston Convention & Exhibition Center (BCEC), USA
Booth:	Exhibit Hall - 1751

For more details about BIO 2025, please visit: <https://convention.bio.org/bio-2025>



Photo 1: HKSTP collaborates with InvestHK, will lead a delegation of 16 prominent life and health technology companies to BIO 2025. For the first time, Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK)—will join the delegation. At the event, representatives from six exhibiting park companies shared their innovative achievements with the media.

(From left: Ms. Menglin Ou, BD Analyst, Arbele Limited; Dr. Bin YE, Founder and CEO, Decode Cure; Dr. Philip LI Hei, Principal Investigator of Centre for Translational Stem Cell



Page 5 of 7

Biology, and Division Chief of Rheumatology and Clinical Immunology and Clinical Assistant Professor, Department of Medicine, School of Clinical Medicine, HKUMed; Ms. Pheona KAN, Director, New Ventures of HKSTP; Dr. Xia JIN, CEO and Co-founder, Immuno Cure BioTech Limited; Mr. See Yeung CHAN, Business Development Officer, BETH; Prof. Zongli ZHENG, Co-Founder, GenEditBio)



Photo 2: Hong Kong Science Park currently hosts over 300 life and health technology enterprises. HKSTP provides comprehensive support, including incubation programs, well-equipped laboratory facilities, and financial assistance to nurture startups and accelerate commercialization.



Appendix: List of Park Companies Participating in BIO 2025:

1. Allegrow Biotech Limited
2. ARBELE Limited
3. Beth Bioinformatics Co., Limited
4. Centre for Translational Stem Cell Biology
5. The Centre for Virology, Vaccinology, and Therapeutics
6. DECODE CURE Limited
7. GenEditBio Limited
8. Great Bay Bio
9. Hong Kong Universal Biologicals Company Limited
10. Immuno Cure Holding (HK) Limited
11. The Institute for Innovation, Translation and Policy Research (ITPR)
12. LEE'S PHARMACEUTICAL (HK) LIMITED
13. Serilink Biotechnology Company Limited
14. Xiaomo Biotech Limited
15. XUXIN (HongKong) Biotechnology Co., Limited
16. Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and



Page 7 of 7

Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org.

Media Enquiries, please contact:

Hong Kong Science and Technology Parks Corporation

Angela Lau

Phone: +852 2629 6633

Email: angela.lau@hkstp.org

Smart GO PR Consultants Limited

Sarah Lee

Phone: +852 4629 5722

Email: sarah.lee@hkcg.com.hk